Literature DB >> 2863836

Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment.

C G Gottfries.   

Abstract

Alzheimer's disease (AD) and senile dementia (SD) are often classified together, but there are genetic, biochemical, neuropathological and clinical arguments for separating them. The well-known Alzheimer lesions in the brains of patients with AD and SD are described, as is the loss of neurons in the locus coeruleus. White matter changes in brains from patients with dementia are discussed and related to AD and SD. Biochemical changes in brains of patients with AD and SD include reduced activity of acetylcholinesterase (AChE) and choline-acetyltransferase (CAT), indicating reduced activity in the acetylcholinergic system. There is also, however, reduced activity in the dopamine (DA), noradrenaline (NA) and 5-hydroxytryptamine (5-HT) system. The active amines are decreased while the end metabolites are decreased to a lesser extent or normal. The levels of the active amines are thought to reflect the number of neurons, while the levels of end metabolites reflect the rate of turnover in the system. 3-Methoxy-4-hydroxyphenylglycol (MHPG) is increased to levels above normal, which may indicate an increased rate of turnover in the NA system. Monoamine oxidase B (MAO-B), which is increased in advanced age, is further increased in patients with AD and SD. It is assumed that this enzyme is localized in extraneuronal tissue, and therefore the increase may reflect a gliosis. In brains from patients with AD and SD neuropeptides are also studied. Only somatostatin and substance P, however, seem to be reduced, indicating selective damage to the neuropeptides. The biochemical changes can be given pathogenetic importance.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2863836     DOI: 10.1007/bf00432208

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  INFLUENCE OF ANTERIOR PITUITARY ON AVOIDANCE LEARNING AND ESCAPE BEHAVIOR.

Authors:  D Dewied
Journal:  Am J Physiol       Date:  1964-07

2.  Vasopressin and memory consolidation.

Authors:  D de Wied; T B van Wimersma Greidanus; B Bohus; I Urban; W H Gispen
Journal:  Prog Brain Res       Date:  1976       Impact factor: 2.453

3.  Brain-decarboxylase activities as indices of pathological change in senile dementia.

Authors:  D M Bowen; P White; R H Flack; C B Smith; A N Davison
Journal:  Lancet       Date:  1974-06-22       Impact factor: 79.321

4.  Microchemical pathology of the cerebral cortex in pre-senile dementias.

Authors:  A Pope; H H Hess; E Lewin
Journal:  Trans Am Neurol Assoc       Date:  1964

5.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

6.  Necropsy evidence of central cholinergic deficits in senile dementia.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

7.  Some cerebral proteins and enzyme systems in Alzheimer's presenile and senile dementia.

Authors:  W Op den Velde; F C Stam
Journal:  J Am Geriatr Soc       Date:  1976-01       Impact factor: 5.562

8.  Prevalence of dementia disorders in institutionalized Swedish old people. The work load imposed by caring for these patients.

Authors:  R Adolfsson; C G Gottfries; L Nyström; B Winblad
Journal:  Acta Psychiatr Scand       Date:  1981-03       Impact factor: 6.392

9.  Neocortical cholinergic neurons in elderly people.

Authors:  P White; C R Hiley; M J Goodhardt; L H Carrasco; J P Keet; I E Williams; D M Bowen
Journal:  Lancet       Date:  1977-03-26       Impact factor: 79.321

10.  Dementia, deep white matter damage and hypertension: 'Binswanger's disease'.

Authors:  I Janota
Journal:  Psychol Med       Date:  1981-02       Impact factor: 7.723

View more
  18 in total

Review 1.  Platelets: A possible glance into brain biological processes in schizophrenia.

Authors:  Eyal Asor; Dorit Ben-Shachar
Journal:  World J Psychiatry       Date:  2012-12-22

Review 2.  Molecular biology and neurobiology of choline acetyltransferase.

Authors:  P M Salvaterra
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

3.  Reversal of scopolamine-induced amnesia of passive avoidance by pre- and post-training naloxone.

Authors:  D K Rush
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level.

Authors:  L Nilsson; A Nordberg; J Hardy; P Wester; B Winblad
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

5.  Intravenous nicotine in Alzheimer's disease: a pilot study.

Authors:  P A Newhouse; T Sunderland; P N Tariot; C L Blumhardt; H Weingartner; A Mellow; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 6.  Critical review of clinical trials in senile dementia--II.

Authors:  J M Orgogozo; R Spiegel
Journal:  Postgrad Med J       Date:  1987-05       Impact factor: 2.401

Review 7.  Depression and senile dementia of the Alzheimer type: a role for moclobemide.

Authors:  V Chan-Palay
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors?

Authors:  L Nilsson; A Adem; J Hardy; B Winblad; A Nordberg
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

9.  MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice.

Authors:  S Murai; H Saito; E Abe; Y Masuda; J Odashima; T Itoh
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  Reversal effect of DM-9384 on scopolamine-induced acetylcholine depletion in certain regions of the mouse brain.

Authors:  E Abe
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.